Know Cancer

forgot password

Intergroup Rhabdomyosarcoma Study Group: Late Effects After Treatment for Rhabdomyosarcoma

5 Years
Not Enrolling
Long-term Effects Secondary to Cancer Therapy in Children, Sarcoma

Thank you

Trial Information

Intergroup Rhabdomyosarcoma Study Group: Late Effects After Treatment for Rhabdomyosarcoma

OBJECTIVES: I. Determine the frequency of self reported health related outcomes in patients
with rhabdomyosarcoma who survived 5 years from diagnosis after treatment on Intergroup
Rhabdomyosarcoma Study Group (IRSG) protocols I, II, III, and IV pilot. II. Determine the
mortality of these patients and compare this mortality to the general population, especially
in the third and fourth decades of life. III. Determine treatment specific risks of
developing a second malignancy following treatment of rhabdomyosarcoma and the potential
genetic influences (family history of cancer). IV. Determine the association between
decreased fertility/offspring and dose, schedule, and total dose of alkylating agents
(especially cyclophosphamide) received during treatment and with selected genitourinary and
paratesticular primaries. V. Determine the effect of the dose and location of therapeutic
radiation for primary head and neck cancer on achieved final height. VI. Determine the
association of therapy with doxorubicin (dose and age when received) with cardiac and
vascular events.

OUTLINE: Patients (or parent or surviving family member) complete the baseline questionnaire
plus other questionnaires (offspring, family history, other topic specific). Medical data is
also collected from past records.

PROJECTED ACCRUAL: Approximately 1600 patients will be accrued for this study.

Inclusion Criteria

DISEASE CHARACTERISTICS: Prior registration on Intergroup Rhabdomyosarcoma Study Group
Study IRS-I, IRS-II, IRS-III, IRS-IV pilot, IRS-V, or IRS-V pilot, or one of the protocols
of IRS-V (D9501, D9502, D9602) AND Survived for 5 years after diagnosis (may be deceased

PATIENT CHARACTERISTICS: Age: 5 and over Performance status: Not specified Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not

PRIOR CONCURRENT THERAPY: See Disease Characteristics

Type of Study:


Study Design:

Primary Purpose: Supportive Care

Principal Investigator

William M. Crist, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Missouri-Columbia


United States: Federal Government

Study ID:




Start Date:

Completion Date:

Related Keywords:

  • Long-term Effects Secondary to Cancer Therapy in Children
  • Sarcoma
  • long-term effects secondary to cancer therapy in children
  • previously treated childhood rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Sarcoma